Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2389 in advanced liver fibrosis (PECHORA)
NCT07069725Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD2389 in Liver Fibrosis (LF) and Liver cirrhosis (LC) (5 arms), sponsored by AstraZeneca. Primary endpoint: Percent change from baseline in uptake of FAP PET radioligand [68Ga]Ga-FAPI-46 in the liver at Day 8. Started May 2025; status: completed.
02
Drugs
AZD2389
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07069725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069725.